Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.81Last Year’s EPS
-0.77Same Quarter Last Year
Strong Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a largely positive growth and execution story: strong revenue and volume growth across oncology and screening, improved gross margins and reduced per-test costs (notably for Reveal), meaningful commercial traction for Shield (high adherence, ADLT reimbursement, EMR integrations, Quest/PathGroup partnerships), and improved profitability trends with a solid cash runway. At the same time, significant near-term investments—primarily in Shield—continue to drive company-wide cash burn and operating expenses, and several important upside catalysts (FDA approvals, additional reimbursements, co-promotion benefits) remain uncertain and are not included in the base guidance. Overall the company is growing rapidly with improving margins and clearer path to profitability, but execution and reimbursement risks and continued screening-related cash burn temper the near-term financial picture.Company Guidance
Strong Top-Line Growth
Total revenue of $281.3M in Q4 2025, up 39% year-over-year; full-year 2025 revenue of $982.0M, up 33% year-over-year; company provided 2026 revenue guidance of $1.25B–$1.28B (+27%–30%).
Oncology Growth and Volume Expansion
Oncology revenue of $189.9M in Q4, up 30% YoY; oncology volumes ~79,000 tests in Q4, up 38% YoY; full-year oncology revenue $683.6M (+26% YoY) with ~276,000 oncology tests (+34% YoY).
Shield Screening Traction
Shield generated $35.1M in Q4 from ~38,000 tests (vs 24,000 in Q3) and $79.7M for the full year from ~87,000 tests; adherence rate of 93% across first 100,000 Shield tests ordered; ADLT reimbursement secured at $1,495 through Dec 2027.
Margin Improvement and Cost Reductions
Non-GAAP gross margin improved to 66% in Q4 and for the full year (up from 63% Q4 prior year and 62% FY2024); Reveal cost per test fell from >$1,000 in Q3 2024 to under $500 in 2025; Shield non-GAAP gross margin improved to 52% in Q4 with Shield cost per test exiting ~ $450.
Biopharma & Data Momentum and CDx Approvals
Biopharma and data revenue grew 18% for FY2025 to $210.1M and Q4 biopharma & data was $54.0M (+9%); company has 25 CDx approvals to date and announced 5 new CDx approvals in the prior 6 months, including first FDA approval for Guardant360 in CRC.
Improving Profitability Trends
Adjusted EBITDA loss improved to -$64.9M in Q4 (vs -$78.4M prior-year quarter) and to -$220.9M for the full year (vs -$257.5M in 2024); free cash flow burn improved to $233M for 2025 (a $42M improvement).
Strong Cash Position and Strategic Investments
Ended 2025 with approximately $1.3B in cash after MetaSight acquisition and financing, providing runway to execute growth plan; acquired MetaSight for $59M upfront plus up to $90M contingent to accelerate R&D and multi-disease pipeline.
Clear 2026 Growth Drivers and Visibility
2026 guidance expects oncology revenue growth of 25%–27% (volumes ~30% growth), screening revenue of $162M–$174M (210k–225k Shield tests), non-GAAP gross margin 64%–65%, and reduced FCF burn of $185M–$195M with the core business expected to be FCF positive excluding Shield.
GH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 19, 2026 | $106.38 | $103.10 | -3.08% |
Oct 29, 2025 | $72.27 | $92.41 | +27.87% |
Jul 30, 2025 | $45.19 | $40.98 | -9.32% |
Apr 30, 2025 | $47.23 | $48.87 | +3.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Guardant Health (GH) report earnings?
Guardant Health (GH) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Guardant Health (GH) earnings time?
Guardant Health (GH) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GH EPS forecast?
GH EPS forecast for the fiscal quarter 2026 (Q1) is -0.81.